Compare VOC & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | XBIT |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Pharmaceuticals and Biotechnology |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 66.8M |
| IPO Year | N/A | 2015 |
| Metric | VOC | XBIT |
|---|---|---|
| Price | $3.40 | $2.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.0K | 27.6K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 12.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $334.12 | N/A |
| Revenue Next Year | N/A | $30.47 |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.63 | $2.09 |
| 52 Week High | $3.84 | $3.44 |
| Indicator | VOC | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 57.82 |
| Support Level | $3.28 | $2.19 |
| Resistance Level | $3.44 | $2.48 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 69.23 | 78.57 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust. It operates in a single operating and reportable segment.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.